New combo therapy aims to stop aggressive lymphoma from coming back
NCT ID NCT07389616
Summary
This study is testing whether a combination of two drugs, Cidabenamine and Azacitidine, can help prevent cancer from returning in people with high-risk T-cell lymphoma who have already received a stem cell transplant from a donor. The goal is to see if this 'maintenance' therapy given after the transplant improves survival and keeps the cancer in remission. The study will enroll about 40 patients to evaluate the safety and effectiveness of this approach.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PERIPHERAL T CELL LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Shanghai General hospital,Shanghai Jiao Tong University School of Medicine
RECRUITINGShanghai, Shanghai Municipality, 200080, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.